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Extramedullary recurrence in multiple myeloma patients has been reported after both autologous and allogeneic hematopoietic
cell transplantation and, more recently, after treatment with so-called new drugs with potent antimyeloma activity. Only a very few
sizable reports focused on its clinical presentation and its incidence, which may be highly underestimated, and most observations
are based on single patients reported from several institutions. Given the unusual sites of recurrence, diagnosis may be rather
difficult and delayed treatment may play a relevant role in prognosis. Here we report a case of a myeloma patient, initially treated
with an allograft, who enjoyed an eleven-year disease-free remission with very good quality of life. She eventually relapsed first
with an extramedullary plasmacytoma in the breast and, two years later, with a right atrial cardiac mass.
1. Introduction
Allografting is considered a potentially curative treatment
for multiple myeloma, although long-term disease control
remains an issue [1]. The frequency of posttransplant
extramedullary recurrence and of extramedullary plasma-
cytoma (EMP) without marrow plasma cell infiltration
is reported variably among institutions even after both
autologous and allogeneic transplantation [2–11]. Similarly,
the selection of diagnostic laboratory tests and imaging
techniques vary among physicians, although early detection
of recurrence may have a significant impact on treatment
outcome. Here we report a case of EMP in the breast and
in the atrium occurring 11 and 13 years after an allograft,
respectively. We also illustrate the potential usefulness of
serum free light chains (FLC) and their ratio in the diagnosis
and followup of EMP.
2. Case Presentation
In June 1998, a 45-year-old lady complained to her family
physician about fatigue, pain in the lower extremities, and
inability to concentrate at her job. The physical examination
revealed the patient to be pale with a hemoglobin of
4.9 g/dL. She was then referred to a hematologist-oncologist.
Immunofixation (IFE) studies of serum and urine were
positive for monoclonal serum proteins (M-proteins). Bone
marrow biopsy submitted in formalin revealed 100%
involvement by monoclonal plasma cells. No cytogenetic
or FISH studies were routinely performed at that time. A
metastatic bone survey showed no osseous abnormality. She
was staged as Durie-Salmon Stage II, International Staging
System II. Induction therapy consisted of 2 cycles of standard
VAD (vincristine, adriamycin, and dexamethasone) regimen.
After the first cycle, the serum and urine remained positive
for M-proteins. A second cycle was given and there was no
adequate response. Given the unsatisfactory response and
the young patient age, she underwent an allograft from her
sister in December 1998, after a conditioning with total
marrow irradiation, busulfan and cyclophosphamide. The
posttransplant course was rather uneventful except for a
hepatitis B reactivation syndrome (after immunosuppressant
therapy) successfully treated with lamivudine. Two years
after the allograft, the bone marrow evaluation showed
complete remission with less than 1% polyclonal plasma
cells. Monoclonal proteins were not detected in serum or
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Table 1: Summary of laboratory testsa,b.
Date Hbc Ca BUN Cr BMG IF-Serumc IF-Urined Remarks
June 1998 Diagnosis 4.9 9.1 10 0.7 3.9 Monoclonal λ Monoclonal λ
Urine protein =
17.9 g/24 hrs, 85% free λ
chains
December 1998
Allogeneic Stem Cell Transplantation
December 1999 11.8 9.4 11 0.6 2.1 Normal Normal Urine protein = 0.2 g/24 hrs
December 2000 14.0 9.6 13 0.7 1.3 Normal Normal
Urine protein too low for
quantification
December 2001
Mammogram: No evidence of
malignancy
14.0 10 14 0.6 1.3 Normal Normal Urine protein too low for
quantification
June 2009
Right breast plasmacytoma (λ): surgery
plus radiation
14.0 10.3 17 0.6 1.6 Normal Normal Urine protein too low for
quantification
July 2011
Right atrium plasmacytoma (λ)
14.1 9.8 14 0.6 Normal Normal 17 mg/dL urinary protein
(random)
October 2012 13.8 9.9 16 0.7 n.d. n.d. n.d.
Urine protein too low for
quantification
a
Serum reference values (abbreviations): hemoglobin (Hb) = 12–15 g/dL, calcium (CA) = 8.2–10.2mg/dL, urea (BUN) = 7–22mg/dL, creatinine (Cr) = 0.2–
1.3mg/dL, beta-2 microglobulin (BMG) = 0.7–3.4mg/dL, burine reference values: 24 hours rotein = less than 0.15 g/24 hrs, random protein = not established,
cIF-Serum: serum immunofixation, dIF-urine: urine immunofixation; n.d.: not done.
urine by IFE, and the 24 hour urine total protein was too
low for quantification (Table 1).
The patient continued to do well and pursued a full-
time job during the eleven year interval after the allograft.
She remained free of myeloma (normal bone marrow, no
evidence of discrete lytic or blastic lesions, negative for
monoclonal proteins in serum and urine from IFE studies,
and urine total protein too low for quantification) until
she complained about a right breast mass located towards
the axilla during a follow-up exam in 2009. Her latest
mammogram in 2001 had been negative. The 2.1 cm mass
consisted of sheets of monoclonal plasma cells and was
diagnosed as solitary plasmacytoma. The EMP was excised
and radiation therapy was delivered for five weeks to the
right breast tumor bed at a total dose of 5040 cGY. At this
time, the bone marrow examination revealed no increase in
plasma cells (<1%), and the CT scan indicated no evidence
of metastatic disease to the chest, abdomen, pelvis, or lytic
or blastic lesions within the skeleton. Serum and urine were
negative for M-proteins (IFE studies), and the protein in
urine was too low for quantification. For the following
two years the patient remained free of any obvious clinical
problem and was able to work full-time. Bone marrow
examinations in 1999, 2000, and 2009 did not showmyeloma
recurrence.
Thirteen years after the allograft, she complained of
shortness of breath and dyspnea on exertion. She denied
any chest pain and any palpitations. The patient was put
on albuterol, but continued to have shortness of breath. An
echocardiogram in her family physician’s office indicated
the presence of a “large right atrial thrombus”, and she was
immediately referred to the hospital emergency department.
A venous ultrasound of the right and left lower extremities
Figure 1: Right cardiac atrial mass shown by CT scan extending
into the inferior vena cava, involving the superior vena cava as it
enters the atrium, and pericardial effusion.
showed no evidence of venous thrombosis. Imaging studies
ruled out pneumothorax and/or pulmonary embolism.
Echocardiogram documented a normal ejection fraction
(60–65%); however, a mass measuring 6.7 × 3.3 cm was seen
in the right atrium encroaching the right atrial wall and a
large pericardial effusion with tamponade. CT confirmed a
large right cardiac atrial mass, extending into the inferior
vena cava and also involving the superior vena cava as it
enters the atrium and the pericardial effusion (Figure 1).
The patient then underwent a pericardial window to drain
the pericardial effusion. The effusion cytology showed that
50% of the cells were plasma cells, which was confirmed
by immunoperoxidase CD138 positive staining. In situ
hybridization stains for kappa and lambda chains indicated
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Table 2: Summary of serum free light chains assays.
Free Kappa (mg/dL)
Normal: 0.33–1.94
Free Lambda (mg/dL)
Normal: 0.57–2.63
Free Kappa/Lambda Ratio
Normal: 0.26–1.65
Chemotherapy with
bortezomib and dexametasone
August 2011 0.78 27.7 0.03 Start Cycle 1
September 2011 0.18 3.3 0.05 Start Cycle 2
0.15 3.2 0.05
0.24 2.8 0.09
October 2011 0.98 2.4 0.41 Start Cycle 3
November 2011 0.87 1.3 0.66 Start Cycle 4
October 2012 0.75 1.2. 0.62
(a) (b)
Figure 2: (a) Diagnosis of extramedullary plasmacytoma confirmed by immunoperoxidase staining for CD138 and (b) in situ hybridization
for lambda chains which confirmed plasma cell monoclonality.
that almost all of the plasma cells were positive for lambda
light chains. The diagnosis of monoclonal plasmacytosis
was made. Biopsy of the pericardial tissue ruled out other
malignancies, amyloidosis, and vasculitis.
Transcatheter biopsy of the right atrial cardiac mass
by fluoroscopic guided road-mapping was performed. The
tissue sample consisted of sheets of plasma cells. The
diagnosis of EMP was confirmed with a combination
of immunoperoxidase staining for CD138, which showed
strong positivity, and in situ hybridization for kappa and
lambda, which confirmed monoclonality since all of the
cells stained for lambda chains (Figures 2(a) and 2(b)).
Flow cytometry was negative due to poor cell survival.
Bone marrow biopsy showed normocellular marrow with
100% donor chimerism. The B cells were polyclonal by
flow cytometry and there was no evidence of monoclonality
within the plasma cells. In situ hybridization revealed a
normal kappa/lambda ratio of 1.4 : 1. MRI of the spine
was unremarkable, without any evidence of canal or neural
foraminal stenosis or of myelomatous disease. Chemother-
apy with monthly cycles of bortezomib and dexamethasone
was initiated and the patient was monitored with serial
serum FLC assay, CT and echocardiography. After four
months, the tumor exhibited a substantial reduction in size
measuring 4.7 cm on echocardiogram and CT scan. Serum
free lambda chain concentration decreased linearly, with
simultaneous increase in the kappa/lambda ratio (Table 2).
The patient is alive and well at this writing, in partial
remission by the International Uniform Response Criteria
for multiple myeloma, 14 years posttransplant [12–14].
She is receiving continuous chemotherapy (bortezomib,
dexamethasone, and now Cytoxan) despite an episode of
DVT in the right leg (3/2012) and a recent syncopal event
(7/2012). The atrial mass measures 4.1 × 0.9 cm in greatest
dimensions by transesophageal echocardiography (11/2012).
3. Discussion
We believe that this case of a lambda chain myeloma patient,
who had an allograft, experienced 2 EMP, after a long clinical
remission, exhibits rather interesting features: (a) a long
disease-free survival without maintenance/consolidation
treatment with very good quality of life after the allograft;
(b) extramedullary relapse as solitary EMP of the breast 11
years after the allograft; (c) two years later a second EMP
of the right cardiac atrium. Bone marrow studies invariably
showed no evidence of marrow plasma cell infiltration with
100% donor chimerism, thus indicating the confinement of
myeloma relapse only to the soft tissues.
Extra-medullary relapse of myeloma with sparing of the
marrow after both autologous and allogeneic transplanta-
tions and, more recently, after therapy with novel agents
such as thalidomide, lenalidomide, and bortezomib, is a
mode of recurrence the frequency of which is undetermined
and may be highly underestimated. Only a few reports
have evaluated EMP incidence, clinical characteristics, and
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prognosis, and most of these are summarised in case reports
[2–11]. Moreover, definitions of EMP lesions vary among
study groups [15].
Varettoni et al. reported an incidence of extramedullary
recurrence of 6% on a series of 1003 myeloma patients,
which was found to be associated with shorter overall and
progression survivals [9]. Zeiser et al. reported a higher
incidence after autologous and allogeneic transplantation
[8]. Numerous sites of involvement such as lungs, soft tissues,
pericardium, skin and central nervous system were reported.
The mechanisms underlying the selective involvement of
extramedullary sites remain undefined. It may be postulated
that thesemechanismsmay be due to recurrence in sanctuary
sites where myeloma cells are resistant to intense therapy,
or to a stronger putative graft-versus-myeloma effect in
the marrow as compared with peripheral tissues after an
allograft.
A major concern for clinicians is the early detection of
the recurrence, because delayed diagnosis may compromise
treatment efficacy. Delayed diagnosis is particularly frequent
when the clinical presentation of the recurrence is rather
unusual, skeletal radiological surveys are negative, and
monoclonal paraproteins are undetectable. Even though
techniques such as MRI and PET imaging may be of value
for monitoring the patient, more readily available and less
expensive laboratory assays should be sought. In our patient,
serum (SPE) and urine protein electrophoreses (UPE), and
IFE (serum and urine) were negative at the time both
breast and atrial masses were noted, therefore indicating
the lack of sensitivity of these tests for the early diagnosis
of solitary EMP. By contrast, only the serum free lambda
chains were ten fold higher than the normal value, and
the free light chain ratio was abnormal, which suggests its
potential usefulness in the early detection of posttransplant
extramedullary recurrence.
Although the role of serum FLC assay is still a matter of
debate to determine stringent clinical complete remission,
it may be particularly relevant for early detection and
followup of EMP where more sensitive methods such as
flow cytometry and/or FISH analysis cannot be performed
on an uninvolved bone marrow [16–18]. In addition to
the light chain myeloma, 95% of the intact monoclonal
immunoglobulin (M-Ig) myelomas have an abnormal serum
FLC concentration and ratio. The malignant plasma cells
most often screte FLC in addition to intact immunoglobu-
lins. Recently in both nonintensive or more intensive therapy
in M-Ig MM, three new developments were reported: (1)
relapse as EMP with a marked increase in serum FLC (also
designated as light chain escape) in the absence of a parallel
rise in M-Ig [19]; (2) clonal change at relapse, identified as
patients who produced a M-Ig at presentation but relapsed
with rising production of serum FLC and stable or falling M-
Ig concentration in the serum [20, 21]; (3) early detection
of relapse of M-IgA MM after autologous SCT by newly
developed Hevylite assay [22], which utilizes antibodies
specific for the intersection of the heavy chain and light chain
of each immunoglobulin, and allows separate quantification
of each immunoglobulin heavy and light chain combination
[23]. Overall, reports suggested that FLC were more sensitive
for the early detection of EMP as compared to other
laboratory tests. We now incorporate the following protocol
in the clinical pathway for monitoring myeloma patients in
clinical remission after transplant: (i) serum FLC assay prior
to the start of treatment; (ii) serum FLC assays every two
weeks for three months to evaluate response to treatment;
(iii) serum FLC assays every three months unless the patient
develops overt myeloma symptoms. A prospective study on a
large cohort of myeloma patients is in progress.
EMP and extramedullary recurrence are rather chal-
lenging to treat. A “standard” therapeutic approach is not
currently available. At present, most treatments are individu-
alized and include a wide range of strategies such as radiation
therapy, new drugs, and donor lymphocyte infusions after an
allograft [2–11]. In our patient, the first EMP in the breast
was treated with surgical excision and radiotherapy that
allowed for a remission duration of 2 years until a new mass
in the right cardiac atrium led to the diagnosis of a second
EMP which responded to bortezomib and dexametasone.
Current large prospective clinical trails should include
side studies that longitudinally evaluate incidence, clinical
presentation, and prognosis of extramedullary recurrence.
Moreover, retrospective analyses on large series of patients
from study groups such as the European Myeloma Network
and/or Bone Marrow Transplantation Registries may be
helpful to better define this clinical entity. Finally, simple and
sensitive diagnostic tests are needed for timely diagnosis that
may allow for improved treatment outcomes.
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